Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034979 | 0.72 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL4035294 | 0.70 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL1942087 | 0.69 | PDE4B (0.32) | JAK1 | |
| SCHEMBL4037698 | 0.69 | CRHR1 (0.37) | CRHR1JAK1 | |
| SCHEMBL13909083 | 0.69 | PIM1 (0.34) | FYNPDE10AMEN1ALDH1A1LMNA | |
| SCHEMBL1942766 | 0.66 | PDE4B (0.32) | KMT2ACDK2 | |
| SCHEMBL4038079 | 0.65 | KHK (0.37) | FYNCRHR1PIM1PIM2 | |
| SCHEMBL4033165 | 0.65 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL4037680 | 0.64 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL1942393 | 0.63 | CRHR1 (0.68) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555265-B1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | EISAI CO.LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1555265-A1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | Eisai Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | CRHR1, MC2R, CRH | FYN 1754/4885CRHR1 1/4885GRM2 126/4885 |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | MC2R, CRHR1, CRHR2 | FYN 1406/4885CRHR1 2/4885GRM2 151/4885 |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | MC2R, CRHR1, CRHR2 | FYN 1313/4885CRHR1 2/4885GRM2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.